Published on 5 Apr 2024 on Zacks via Yahoo Finance
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
AstraZeneca AZN announced positive data from the phase III ADRIATIC study, which evaluated its blockbuster cancer drug, Imfinzi (durvalumab), for treating patients with limited-stage small cell lung cancer (LS-SCLC), an aggressive form of lung cancer.
The dual primary endpoints of this global phase III study are overall survival (OS) and progression-free survival (PFS).
Data from the study showed that treatment with Imfinzi led to statistically significant and clinically meaningful improvement in the OS and PFS in patients with LS-SCLC whose disease has not progressed after treatment with concurrent chemoradiotherapy (cCRT) versus placebo following cCRT.